Wall Street analyst estimates for Bio-Rad Laboratories, Inc. (BIO): consensus price target and buy/hold/sell recommendations.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics.
Analyst Consensus
| Strong Buy | 1 |
| Buy | 7 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (−2 sell to +2 buy) | 0.64 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $2.23 | ||
| 2026-08-04 | $2.62 | $1.75 | +49.7% |
| 2026-04-30 | $1.89 | $1.97 | -4.1% |
| 2026-02-12 | $2.51 | $2.57 | -2.3% |
| 2025-10-29 | $2.26 | $2.30 | -1.7% |
| 2025-07-31 | $2.61 | $1.93 | +35.2% |
| 2025-05-01 | $2.54 | $1.73 | +46.8% |
| 2025-02-13 | $2.90 | $2.86 | +1.4% |
Valuation Ratios
| P/E Ratio | 45.11 |
| Price / Book | 1.39 |
| EV / EBITDA | 20.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.16B | $2.29B | $2.31B | $2.55B | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Cost of Revenue | $930.1M | $972.8M | $1.07B | $1.05B | $1.11B | $1.28B | $1.23B | $1.24B | $1.19B | $1.24B |
| Gross Profit | $1.14B | $1.19B | $1.22B | $1.26B | $1.44B | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Research & Development | $205.9M | $250.3M | $199.2M | $202.7M | $217.8M | $260.6M | $256.9M | $247.4M | $295.9M | $256.9M |
| Selling, General & Admin | $816.7M | $808.9M | $833.3M | $824.6M | $798.8M | $877.1M | $827.8M | $841.7M | $814.0M | $819.9M |
| Operating Expenses | $1.02B | $1.06B | $1.03B | $1.03B | $1.02B | $1.14B | $1.08B | $1.09B | $1.11B | $1.08B |
| Operating Income | $53.2M | $116.7M | -$108.6M | $229.7M | $421.3M | $500.3M | $482.6M | $337.8M | $269.0M | $270.5M |
| EBITDA | $206.4M | $269.5M | $674.7M | $2.42B | $5.08B | $5.59B | -$4.53B | -$654.8M | -$2.14B | $1.21B |
| Interest Expense | $23.4M | $23.0M | $24.0M | $23.4M | $21.9M | $1.6M | $38.1M | $49.4M | $48.9M | $49.0M |
| Pre-tax Income | $41.6M | $97.8M | $507.4M | $2.26B | $4.92B | $5.45B | -$4.70B | -$850.1M | -$2.34B | $995.5M |
| Income Tax | $13.4M | -$16.9M | $146.4M | $502.4M | $1.10B | $1.19B | -$1.08B | -$212.8M | -$498.3M | $235.6M |
| Net Income | $28.1M | $114.7M | $361.0M | $1.76B | $3.81B | $4.25B | -$3.63B | -$637.3M | -$1.84B | $759.9M |
| EPS | $0.88 | $4.12 | $12.10 | $58.93 | $127.86 | $142.61 | $-121.79 | $-21.82 | $-65.36 | $27.87 |
| EPS (Diluted) | $0.88 | $4.07 | $11.94 | $58.27 | $126.20 | $140.83 | $-121.79 | $-21.82 | $-65.36 | $27.87 |
| Shares Outstanding (Diluted) | 29.6 M | 30.0 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 29.8 M | 29.2 M | 28.2 M | 27.3 M |
Price
| Price | $372.18 (closing price, October 30, 2026) |
| Market Cap | $10.0B |
| Exchange | NYSE |
| Country | US |
Related companies: TECH · RGEN · BRKR · MRVI · TMO · DHR · RVTY
Explore sector: Healthcare · Medical - Devices
More sections of BIO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks